ABEONA THERAPEUTICS INC
NASDAQ: ABEO (Abeona Therapeutics Inc.)
Last update: 11 hours ago4.20
0.01 (0.24%)
| Previous Close | 4.19 |
| Open | 4.15 |
| Volume | 2,483,311 |
| Avg. Volume (3M) | 1,115,359 |
| Market Cap | 215,369,856 |
| Price / Earnings (TTM) | 6.56 |
| Price / Earnings (Forward) | 18.66 |
| Price / Sales | 755.07 |
| Price / Book | 1.67 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.630 |
| Total Debt/Equity (MRQ) | 57.92% |
| Current Ratio (MRQ) | 4.90 |
| Operating Cash Flow (TTM) | -59.88 M |
| Levered Free Cash Flow (TTM) | -39.71 M |
| Return on Assets (TTM) | -49.95% |
| Return on Equity (TTM) | -271.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Abeona Therapeutics Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.5 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.75 |
|
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.84% |
| % Held by Institutions | 63.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Jun 2025 | 2,676,000 |
| Western Standard Llc | 30 Jun 2025 | 2,091,598 |
| Boone Capital Management Llc | 30 Jun 2025 | 1,254,658 |
| Propel Bio Management, Llc | 30 Jun 2025 | 974,022 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 376.19%) | Buy |
| 20.00 (Oppenheimer, 376.19%) | Buy | |
| Median | 20.00 (376.19%) | |
| Average | 20.00 (376.19%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Oct 2025 | 20.00 (376.19%) | Buy | 5.41 |
| 18 Aug 2025 | 20.00 (376.19%) | Buy | 6.91 | |
| Oppenheimer | 15 Aug 2025 | 20.00 (376.19%) | Buy | 7.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |